

June 15, 1965

Dr. Ivan F. Bennett
Ely Lilly and Company
RR 18, Box 285
Indianapolis 24, Indiana

Dear Ivan:

Thank you very much for your letter of June 4, and the detailed information regarding your experiences with cycloserine. After reading all the data, my associates and I have become particularly interested in an opportunity for clinical trials with cycloserine in a group of severe mentally ill. The effects in altering brain function over a prolonged period which you noted and which others have reported, and which have generally been regarded as side effects, are precisely the focus of our interest. We would like to induce prolonged changes in brain function in these patients.

For this reason and following the report of Dr. Vitek, we would be particularly interested in a trial of l-cycloserine if that is available. If not, the racemic mixture also seems to be effective.

Would you be able to make supplies of cycloserine available to us, and provide the necessary FDA clearance? If not, whom may we contact at Lilly Laboratories for such a collaboration?

Many thanks for your assistance.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp